捷克儿童1型糖尿病的人群筛查:首批1%儿科人群的结果
Betty项目是捷克全国性1型糖尿病筛查计划,采用两级胰岛自身抗体检测流程,在2024年4月至2026年2月间采集了19044份毛细血管筛查样本(占儿科人群1%)。一般人群中多抗体阳性率为0.39%(95%CI:0.30%–0.51%),一级亲属中为2.8%(95%CI:2.1%–3.7%);201名毛细血管筛查非阴性儿童中102例经静脉样本确诊为早期1型糖尿病。
要点
- 筛查覆盖2–17.9岁儿童,不论有无1型糖尿病家族史,采用两级胰岛自身抗体检测流程。
- 一般人群多抗体阳性率为0.39%(95%CI:0.30%–0.51%),一级亲属中为2.8%(95%CI:2.1%–3.7%)。
- 201名毛细血管筛查非阴性儿童中102例经静脉样本确诊早期1型糖尿病,83例完成分期。
核心结论
- 该全国性1型糖尿病筛查项目成功覆盖约1%的捷克儿科人群,证明基于EDENT1FI通用方案实施人群胰岛自身抗体筛查是可行的。
- 结果为捷克国家医疗体系未来可能实施常规人群1型糖尿病筛查提供了重要基础,并为考虑类似筛查方案的其他国家提供了有价值的参考。
研究设计与样本
- Betty项目是捷克在EDENT1FI框架下建立的全国性1型糖尿病筛查项目,报告检测1%捷克儿科人群后的结果。
- 筛查对象为2–17.9岁儿童,无论是否有1型糖尿病家族史。
- 采用两级流程检测胰岛特异性自身抗体(抗GAD、抗IA2、抗ZnT8和IAA):毛细血管筛查样本一级检测(筛查ELISA,给出三种自身抗体的汇总信号)阳性后,同一样本在EDENT1FI参考实验室用4种二级检测(LIPS或RBA)复检个体自身抗体。
- 检测到任何自身抗体时要求静脉样本确认;静脉样本确认多种自身抗体则诊断为早期1型糖尿病,并按个体估计进展至临床糖尿病的速率提供随访。
- 仅确认单一自身抗体的儿童在EDENT1FI方案之外接受强度较低的随访。
主要发现
- Betty项目于2024年4月至2026年2月间收集了19044份毛细血管筛查样本(占儿科人群1%),样本来自270个筛查点,多在初级保健机构采集,另有4.1%样本通过家庭采样采集。
- 大多数参与者(89.7%)来自一般人群,无1型糖尿病一级亲属。
- 一般人群中多抗体阳性率为0.39%(95%CI:0.30%–0.51%),1型糖尿病者一级亲属中多抗体阳性率为2.8%(95%CI:2.1%–3.7%)。
- 截至撰稿时,201名毛细血管筛查非阴性儿童中,102例经确认性静脉样本诊断为早期1型糖尿病,83例完成1型糖尿病分期:77例(93%)为1期,4例(4.8%)为2期,2例(2.4%)为3期。
- 另有7名经毛细血管筛查识别的儿童在完成分期前已表现为3期1型糖尿病;所有前来分期和教育的家庭均同意长期随访。
临床怎么用
- 所有前来分期和教育的家庭均同意长期随访。
- 确认多种自身抗体的儿童被诊断为早期1型糖尿病,并接受根据其个体估计进展至临床糖尿病速率定制的随访。
- 仅确认单一自身抗体的儿童在EDENT1FI方案之外接受强度较低的随访。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「局限性」,故未列出该栏;全文请点「阅读原文」。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Aims EDENT1FI is a European initiative aiming to implement a roadmap for screening, monitoring and prevention of childhood Type 1 diabetes (T1D). The Betty project is a nationwide T1D screening program recently established in Czechia within the framework of EDENT1FI. Here we report its results after having tested 1% of the Czech paediatric population. Methods The screening targets children aged 2–17.9 years, regardless of whether they have a family history of T1D. It follows a two-step process for detecting islet-specific autoantibodies (anti-GAD, anti-IA2, anti-ZnT8 and IAA). If the capillary screening sample is positive in the first-level test (screening ELISA yielding a summary signal of three autoantibodies), the same sample is retested at the EDENT1FI reference laboratory using a battery of 4 second-level tests for individual autoantibodies (LIPS or RBA). When any autoantibody is detected, a venous sample is requested for confirmation. If multiple autoantibodies are confirmed from this venous sample, the child is diagnosed with early-stage T1D and offered follow-up tailored to their individual estimated rate of progressing to clinical diabetes. Children with only a single confirmed autoantibody are offered a less intensive follow-up outside the EDENT1FI protocol. Results The Betty project collected 19 044 capillary screening samples (1% of the paediatric population) between April 2024 and February 2026. Samples were collected across 270 screening sites mostly at primary care and via home sampling (4.1% samples). The majority of participants (89.7%) were from the general population having no first-degree relative (FDR) with T1D. We found a prevalence of multiple autoantibodies of 0.39% (95% CI: 0.30%–0.51%) in the general population and 2.8% (95% CI: 2.1%–3.7%) prevalence among FDRs of subjects with T1D. At the time of writing, of 201 children with non-negative capillary screening sample, 102 were diagnosed with early-stage T1D by a confirmatory venous sample and 83 had their T1D stage assessed: 77 (93%) were in Stage 1, 4 (4.8%) in Stage 2 and 2 (2.4%) in Stage 3. Further seven children, who were identified by capillary screening, manifested with Stage 3 T1D before their staging could be completed. All families who came for staging and education visits consented to long-term follow-up. Conclusions This nationwide T1D screening program successfully reached approximately 1% of the Czech paediatric population, demonstrating the feasibility of implementing population-based islet autoantibody screening based on the common EDENT1FI protocol. These findings provide an important foundation for the potential future implementation of routine population-based T1D screening within the Czech national healthcare system and offer valuable insights for other countries considering similar screening programmes.
引用
- Diabetes, Obesity and Metabolism:Population‐Based Screening for Type 1 Diabetes in Czechia: Results From the First 1% of the Paediatric Population
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。